Indivior Plc Spon (NASDAQ:INVVY) Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Indivior Plc Spon (NASDAQ:INVVY) from a hold rating to a sell rating in a research report sent to investors on Wednesday, October 18th.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Shares of Indivior Plc Spon (NASDAQ INVVY) traded up 0.4517% during midday trading on Wednesday, reaching $22.2399. 1,506 shares of the company’s stock were exchanged. The company’s 50 day moving average is $21.75 and its 200-day moving average is $22.08. Indivior Plc Spon has a 12 month low of $17.18 and a 12 month high of $27.47. The stock has a market cap of $3.21 billion and a PE ratio of 40.0719.

TRADEMARK VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/28/indivior-plc-spon-invvy-lowered-to-sell-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Indivior Plc Spon (INVVY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Indivior Plc Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior Plc Spon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply